Modality
ASO
MOA
BCL-2i
Target
PCSK9
Pathway
Notch
MigraineMCLPancreatic Ca
Development Pipeline
Preclinical
~Sep 2017
→ ~Dec 2018
Phase 1
~Mar 2019
→ ~Jun 2020
Phase 2
~Sep 2020
→ ~Dec 2021
Phase 3
Mar 2022
→ Jun 2027
Phase 3Current
NCT03875492
661 pts·MCL
2023-04→2026-07·Terminated
NCT08174683
2,213 pts·Migraine
2025-06→2027-01·Not yet recruiting
NCT05365974
47 pts·MCL
2022-03→2027-06·Completed
2,921 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2026-07-244mo awayPh3 Readout· MCL
2027-01-1510mo awayPh3 Readout· Migraine
2027-06-171.2y awayPh3 Readout· MCL
Trial Timeline
Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3
P3
Complet…
P3
Termina…
P3
Not yet…
Catalysts
Ph3 Readout
2026-07-24 · 4mo away
MCL
Ph3 Readout
2027-01-15 · 10mo away
Migraine
Ph3 Readout
2027-06-17 · 1.2y away
MCL
CompletedTerminatedNot yet recruiting|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03875492 | Phase 3 | MCL | Terminated | 661 | PASI75 |
| NCT08174683 | Phase 3 | Migraine | Not yet recr... | 2213 | ACR20 |
| NCT05365974 | Phase 3 | MCL | Completed | 47 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5501 | Pfizer | Phase 1 | BTK | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| Zanusertib | AbbVie | Approved | PCSK9 | |
| Tezecilimab | Takeda | NDA/BLA | Tau | |
| Rimaosocimab | Amgen | Preclinical | FXIa | |
| GIL-4361 | Gilead Sciences | Preclinical | PCSK9 | |
| REG-2172 | Regeneron | Phase 1/2 | PCSK9 | |
| BMR-8377 | BioMarin | Phase 1/2 | PCSK9 | |
| INC-5849 | Incyte | Phase 2 | PCSK9 |